Cargando…
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard first-line therapy for metastatic lung adenocarcinoma harboring sensitive EGFR mutations. Tumor surface programmed death-ligand 1 (PD-L1) is expressed in some metastatic EGFR-mutated lung adenocarcinoma, but its...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167989/ https://www.ncbi.nlm.nih.gov/pubmed/32092879 http://dx.doi.org/10.3390/biomedicines8020036 |
_version_ | 1783523610244153344 |
---|---|
author | Hsu, Ping-Chih Wang, Chih-Wei Kuo, Scott Chih-Hsi Lin, Shu-Min Lo, Yu-Lun Huang, Allen Chung-Cheng Chiu, Li-Chung Yang, Cheng-Ta |
author_facet | Hsu, Ping-Chih Wang, Chih-Wei Kuo, Scott Chih-Hsi Lin, Shu-Min Lo, Yu-Lun Huang, Allen Chung-Cheng Chiu, Li-Chung Yang, Cheng-Ta |
author_sort | Hsu, Ping-Chih |
collection | PubMed |
description | Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard first-line therapy for metastatic lung adenocarcinoma harboring sensitive EGFR mutations. Tumor surface programmed death-ligand 1 (PD-L1) is expressed in some metastatic EGFR-mutated lung adenocarcinoma, but its impact on the efficacy of EGFR-TKIs is unclear. We retrospectively investigated 117 untreated metastatic lung EGFR mutated adenocarcinoma patients with a PD-L1 immunohistochemistry test. The PD-L1 expression level was classified by tumor proportion scores (TPS). Forty-five patients had negative expression (TPS < 1%), 45 had a weak expression (TPS 1–49%), and 27 had a strong expression (≥50%). All patients recruited in this study received EGFR-TKIs as a first-line therapy. No significant differences were observed for objective response rates (68.9% versus 62.2% versus 73.1%, p = 0.807) and median time to treatment failure (TTF) (12.17 versus 13.17 versus 11.0 months, p = 0.443) of first-line EGFR-TKIS among the three groups of patients (negative versus weak versus strong). The median overall survival was 21.27 versus 20.63 versus 19.43 months among the three groups of patients (p = 0.77). Our results demonstrated that PD-L1 did not affect the efficacy of first-line EGFR-TKIs in metastatic EGFR mutated lung adenocarcinoma. Thus, EGFR-TKIs are suggested as the preferred clinical therapy for these patients, despite their PD-L1 levels. |
format | Online Article Text |
id | pubmed-7167989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71679892020-04-21 The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma Hsu, Ping-Chih Wang, Chih-Wei Kuo, Scott Chih-Hsi Lin, Shu-Min Lo, Yu-Lun Huang, Allen Chung-Cheng Chiu, Li-Chung Yang, Cheng-Ta Biomedicines Article Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard first-line therapy for metastatic lung adenocarcinoma harboring sensitive EGFR mutations. Tumor surface programmed death-ligand 1 (PD-L1) is expressed in some metastatic EGFR-mutated lung adenocarcinoma, but its impact on the efficacy of EGFR-TKIs is unclear. We retrospectively investigated 117 untreated metastatic lung EGFR mutated adenocarcinoma patients with a PD-L1 immunohistochemistry test. The PD-L1 expression level was classified by tumor proportion scores (TPS). Forty-five patients had negative expression (TPS < 1%), 45 had a weak expression (TPS 1–49%), and 27 had a strong expression (≥50%). All patients recruited in this study received EGFR-TKIs as a first-line therapy. No significant differences were observed for objective response rates (68.9% versus 62.2% versus 73.1%, p = 0.807) and median time to treatment failure (TTF) (12.17 versus 13.17 versus 11.0 months, p = 0.443) of first-line EGFR-TKIS among the three groups of patients (negative versus weak versus strong). The median overall survival was 21.27 versus 20.63 versus 19.43 months among the three groups of patients (p = 0.77). Our results demonstrated that PD-L1 did not affect the efficacy of first-line EGFR-TKIs in metastatic EGFR mutated lung adenocarcinoma. Thus, EGFR-TKIs are suggested as the preferred clinical therapy for these patients, despite their PD-L1 levels. MDPI 2020-02-19 /pmc/articles/PMC7167989/ /pubmed/32092879 http://dx.doi.org/10.3390/biomedicines8020036 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hsu, Ping-Chih Wang, Chih-Wei Kuo, Scott Chih-Hsi Lin, Shu-Min Lo, Yu-Lun Huang, Allen Chung-Cheng Chiu, Li-Chung Yang, Cheng-Ta The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma |
title | The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma |
title_full | The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma |
title_fullStr | The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma |
title_full_unstemmed | The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma |
title_short | The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma |
title_sort | co-expression of programmed death-ligand 1 (pd-l1) in untreated egfr-mutated metastatic lung adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167989/ https://www.ncbi.nlm.nih.gov/pubmed/32092879 http://dx.doi.org/10.3390/biomedicines8020036 |
work_keys_str_mv | AT hsupingchih thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT wangchihwei thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT kuoscottchihhsi thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT linshumin thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT loyulun thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT huangallenchungcheng thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT chiulichung thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT yangchengta thecoexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT hsupingchih coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT wangchihwei coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT kuoscottchihhsi coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT linshumin coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT loyulun coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT huangallenchungcheng coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT chiulichung coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma AT yangchengta coexpressionofprogrammeddeathligand1pdl1inuntreatedegfrmutatedmetastaticlungadenocarcinoma |